Prevalence and treatment of peptic ulcer at educational Al Hussein Hospital and review of antibiotics from global sources
Keywords:
helicobacter pylori, treatment, educational, Al Hussein hospitalAbstract
Infection with Helicobacter pylori (H. pylori) is a prevalent global infection that is a leading cause of peptic ulcer disease and stomach cancer. Determine the prevalence of H. Pylori in the province of Thi-Qar from 2017 to 2018. Data was collected utilizing a periscope on the second floor of Educationa Al Hussein Hospital's Gastroenterology Unit for patients with gastrointestinal ulcers on the basis of age, gender, housing area, and month. A survey of the therapies utilized throughout the world was performed to get information on ulcer therapy. The current study found that the number of people infected with H. pylori in 2017 was higher than the number of people infected in 2018, in both sexes, with the overall number of people infected in 2017 being higher than the total number of people infected in 2018. (250). Females between the ages of 15 and 35, living in the countryside during the month of May, had a significant frequency of H. pylori with gastric ulcer. The treatment of stomach ulcers employed in the gastrointestinal unit of the patients was positive tests for H.pylori infection.
Downloads
References
Brown LM. Helicobacter pylori: Epidemiology and routes of transmission. Epidemiol Rev 2000;22:283-97.
Ratnakar C. Prevalence of helicobacter pylori infection in disorders of the upper gastrointestinal tract in South India. Natl Med J India 1998;11:5-8.
Ozbek A, Ozbek E, Dursun H, Kalkan Y, Demirci T. Can helicobacter pylori invade human gastric mucosa?: An in vivo study using electron microscopy, immuno histochemical methods, and real-time polymerase chain reaction. J Clin Gastroenterol 2010;44:416-22.
Mandeville KL, Krabshuis J, Ladep NG, Mulder CJ,Quigley EM, Khan SA, et al. Gastroenterology in developing countries: Issues and advances. World J Gastroenterol 2009;15:2839-54.
Das JC, Paul N. Epidemiology and pathophysiology of helicobacter pylori infection in children. Indian J Pediatr 2007;74:287-90.
Adlekha S, Chadha T, Krishnan P, Sumangala B. Prevalence of helicobacter pylori infection among patients undergoing upper gastrointestinal endoscopy in a medical college hospital in Kerala, India. Ann Med Health Sci Res 2013;3:559-63.
Tarkhashvi l i N, Beriashvili R, Chakvetadze N, Moistsrapishvili M, Chokheli M, Sikharulidze M, et al. Helicobacter pylori infection in patients undergoing upper endoscopy, republic of Georgia. Emerg Infect Dis 2009;15:504-5.
Isabelle N, Ben V, Robert I, Michael R. Helicobacter pylori status among patients undergoing gastroscopy in rural Northern Alberta. Canadian Family Physician 2016;62:e547-54.
Shokrzadeh L, Baghaei K, Yamaoka Y, Shiota S, Mirsattari D, Porhoseingholi A, et al. Prevalence of helicobacter pylori infection in dyspeptic patients in Iran. Gastroenterol Insights 2012;4:247.
Pahwa R, Neeta, Kumar V, Kohli K. Clinical manifestations, causes and management strategies of peptic ulcer disease. Int. J. Pharm. Sci. Drug. Res., 2010; 2(2): 99-106.
Friedman S L, McQuaid K R, Grendell J H. Current Diagnosis & Treatment in Gastroenterology 2nd ed. McGraw-Hill/Appleton & Lange, 2002; 569-597.
Chey WD, Wong BCY. American college of gastroenterology guideline on the management of Helicobacter pylori Infection. Am. J. Gastroenterol. 2007;102 (8):1808-25.
Loyd RA, McClellan DA. Update on the evaluation and management of functional dyspepsia. Am. Fam. Physician. 2011;83: 547-552.
Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versusclarithromycin-based triple therapy: a randomised, open label, non-inferiority, phase 3 trial. Lanc. 2011;377:905-913
Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using asingle capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: A prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol. 2003;98:562- 567.
Fuccio L, Eusebi LH and Bazzoli F. Gastric cancer, Helicobacter pylori infection and other risk factors. World J .Gastrointest. Oncol. 2010; 2: 342-347.
Alakkari A, Zullo Aand O’Connor HJ. Helicobacter pylori and non malignant diseases. Helicobacter 2011; 16(1): 33-37.
Hajiani e, hashemi j and vosoghi t. comparison of a 10 day triple and a two-week quadruple therapy in eradicating helicobacter pylori infection in patients referred to imam khomeini hospital clinics ahwaz, iran. jundishapur journal of natural pharmaceutical products, 2008; 3(1): 45-52.
Yasir S, Moin F and Akhtar S M.Frequency of Helicobacter Pylori Infection on Histopathology in Patients with Dyspepsia. American Journal of Clinical Medicine Research, 2014; 2(3): 53-56.
Dong WG, Cheng CS, Liu SP, et al. Epidemiology of peptic ulcer disease in Wuhan area of China from 1997 to 2002. World J. Gastroenterol., 2004; 10(22): 3377-3379.
Marques SB, Mattar R, Artifon EL, et al. High prevalence of duodenal ulcer in a tertiary care hospital in the city of São Paulo, SP, Brazil. Arq. Gastroenterol, 2011; 48(3): 171-174.
Chao Wu H , Guang Tuo B, Min Wu W , et al. Prevalence of Peptic Ulcer in Dyspeptic Patients and the Influence of Age, Sex, and Helicobacter pylori Infection, Digestive diseases and sciences, 2008; 53(10): 2650-2656.
Helicobacter pylori seropositivity rates in Iraq. Helicobacter, 2008; 13(4): 306-307.
Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211–223.
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012;61:646–664.
Di Mario F, Cavallaro LG, Scarpignato C. ‘Rescue’ therapies for the management of Helicobacter pylori infection. Dig Dis. 2006;24:113–130.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
